Skip to main content

January/February 2019, Vol 12, Special Issue: Payers’ Perspectives in Oncology: ASH 2018 Highlights

View Additional ASH 2018 Coverage

Leukemia, Oncology
MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemo­immunotherapy in Relapsed/Refractory CLL
Phoebe Starr
Read More
Lymphoma
Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
Charles Bankhead
Read More
FDA Approvals
Selinexor a Promising Oral Option in Triple-Class Refractory Multiple Myeloma
Wayne Kuznar
Read More
Practice Management
Hospital Readmissions for Venous Thromboembolism a Substantial Cost in Patients with Cancer
Chase Doyle
Read More
Page 3 of 3
Results 21 - 24 of 24